Cargando…
A novel nano-iron supplement to safely combat iron deficiency and anaemia in young children: The IHAT-GUT double-blind, randomised, placebo-controlled trial protocol
Background: Iron deficiency and its associated anaemia (IDA) are the leading forms of micronutrient malnutrition worldwide. Here we describe the rationale and design of the first clinical trial evaluating the efficacy and safety of an innovative nano iron supplement, iron hydroxide adipate tartrate...
Autores principales: | Pereira, Dora I.A., Mohammed, Nuredin I., Ofordile, Ogochukwu, Camara, Famalang, Baldeh, Bakary, Mendy, Thomas, Sanyang, Chilel, Jallow, Amadou T., Hossain, Ilias, Wason, James, Prentice, Andrew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266659/ https://www.ncbi.nlm.nih.gov/pubmed/30569038 http://dx.doi.org/10.12688/gatesopenres.12866.2 |
Ejemplares similares
-
A novel nano-iron supplement versus standard treatment for iron deficiency anaemia in children 6–35 months (IHAT-GUT trial): a double-blind, randomised, placebo-controlled non-inferiority phase II trial in The Gambia
por: Mohammed, Nuredin I., et al.
Publicado: (2023) -
The IHAT-GUT Iron Supplementation Trial in Rural Gambia: Barriers, Facilitators, and Benefits
por: Stelle, Isabella, et al.
Publicado: (2021) -
Hemoglobin point-of-care testing in rural Gambia: Comparing accuracy of HemoCue and Aptus with an automated hematology analyzer
por: Nass, Stefan A., et al.
Publicado: (2020) -
Respiratory infections drive hepcidin-mediated blockade of iron absorption leading to iron deficiency anemia in African children
por: Prentice, Andrew M., et al.
Publicado: (2019) -
Hepcidin-guided screen-and-treat interventions for young children with iron-deficiency anaemia in The Gambia: an individually randomised, three-arm, double-blind, controlled, proof-of-concept, non-inferiority trial
por: Wegmüller, Rita, et al.
Publicado: (2022)